Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Feb 17, 2023
Date Accepted: Apr 30, 2023

The final, peer-reviewed published version of this preprint can be found here:

A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial

Kamp K, Clark-Snustad K, Yoo L, Winders S, Cain K, Levy RL, Dey N, Lee S, Keefer L, Heitkemper M

A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial

JMIR Res Protoc 2023;12:e46307

DOI: 10.2196/46307

PMID: 37285195

PMCID: 10285620

A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial

  • Kendra Kamp; 
  • Kindra Clark-Snustad; 
  • Linda Yoo; 
  • Samantha Winders; 
  • Kevin Cain; 
  • Rona L Levy; 
  • Neelendu Dey; 
  • Scott Lee; 
  • Laurie Keefer; 
  • Margaret Heitkemper

ABSTRACT

Background:

Despite pharmacological treatment, individuals with inflammatory bowel disease (IBD) experience a variety of symptoms including abdominal pain, fatigue, anxiety, and depression. Few non-medical self-management interventions are available for people with IBD. A validated comprehensive self-management (CSM) intervention is effective for patients with irritable bowel syndrome who can have symptoms similar to individuals with IBD. We created a modified CSM intervention tailored to individuals with IBD (CSM-IBD). The CSM-IBD is an 8-week online program with weekly check-ins with a registered nurse.

Objective:

The primary objective of this pilot study is to determine the feasibility and acceptability of study procedures and the CSM-IBD intervention and to evaluate preliminary efficacy on quality of life and daily symptoms for a future randomized control trial. Additionally, we will examine the association of socioecological, clinical, and biological factors with symptoms at baseline and response to intervention.

Methods:

We are conducting a pilot randomized controlled trial of the CSM-IBD intervention. We plan to enroll 54 participants who will be randomized (2:1) into the CSM-IBD program or usual care. Outcomes data will be assessed at baseline, immediately post, and 3-months post intervention. Participants in the usual care group will have access to the intervention after study participation.

Results:

This project is funded by the National Institutes of Nursing Research and reviewed by the University of Washington IRB. Recruitment is set to begin February 2023.

Conclusions:

This pilot study will evaluate the feasibility and efficacy of a self-management intervention (online program with weekly check-ins with a registered nurse) that aims to improve symptom management in individuals with IBD. Long term, we aim to validate a self-management intervention will improve patient quality of life, reduce direct and indirect costs related to IBD, and that is culturally appropriate and accessible, particularly in rural and underserved communities. Clinical Trial: ClinicalTrials.gov NCT05651542; https://clinicaltrials.gov/ct2/show/NCT05651542


 Citation

Please cite as:

Kamp K, Clark-Snustad K, Yoo L, Winders S, Cain K, Levy RL, Dey N, Lee S, Keefer L, Heitkemper M

A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial

JMIR Res Protoc 2023;12:e46307

DOI: 10.2196/46307

PMID: 37285195

PMCID: 10285620

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Advertisement